U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 51 - 60 of 480 results

Status:
US Previously Marketed
Source:
Levonor by Nordmark (Purdue Frederick)
(1957)
Source URL:
First approved in 1957
Source:
Levonor by Nordmark (Purdue Frederick)
Source URL:

Class:
POLYMER

Status:
US Previously Marketed
Source:
INULIN AND SODIUM CHLORIDE by ISO TEX
(1940)
Source URL:
First approved in 1940

Class:
POLYMER

Conditions:

Inulin is a water soluble storage polysaccharide used as a prebiotic, fat replacer, sugar replacer, and texture modifier. Inulin is a soluble fiber which is not digested by human enzymes and produces distinctive fiber-alike results on the effectiveness of the gut, thus, lowering the pH of intestine, providing assistance in relieving constipation and increasing stool load or rate. Inulin decrease the risk of many diseases of the intestinal tract, particularly irritable bowel diseases and colon cancer. Inulin products contain mainly short-chain molecules which enhance the sweetness of sucrose up to 35%, thus it is useful to partially replace sucrose molecule’s flavor. Inulin has been proved an attractive applicant as a low-calorie bulking agent in chocolate, mostly in combination with a polyol which replaces sugar contents without any effect on fat contents. Further uses of inulin include colon specific drug administration and stabilizing and adjuvating vaccine formulations.
Status:
Possibly Marketed Outside US
Source:
NCT02280772: Phase 4 Interventional Completed Obesity
(2015)
Source URL:
First approved in 2013

Class:
POLYMER

structurally diverse
Status:
US Approved OTC
Source:
21 CFR 346.18(b) anorectal:astringent witch hazel (haramelis water)
Source URL:
First marketed in 1921

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT02658591: Not Applicable Interventional Active, not recruiting Obesity
(2016)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT03135015: Phase 1 Interventional Completed Insulin Resistance, Diabetes
(2017)
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Investigational
Source:
NCT04381026: Not Applicable Interventional Completed Menopause
(2017)
Source URL:

Class:
STRUCTURALLY DIVERSE